within Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IX17_Psma100718f;

model Psma100718f
  extends Pharmacolibrary.Drugs.ATC.V.V09IX17;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>V09IX17</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>PSMA-1007 labeled with fluorine-18 is a radiopharmaceutical used in positron emission tomography (PET) imaging for the detection of prostate-specific membrane antigen (PSMA)–positive prostate cancer lesions. It is not used as a therapeutic agent but as a diagnostic tracer, approved for clinical use in numerous countries for prostate cancer imaging.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data in adult male patients with prostate cancer undergoing PET imaging after intravenous injection.</p><h4>References</h4><ol><li><p>Kim, SB, et al., &amp; Kim, SE (2023). Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [. <i>Molecular pharmaceutics</i> 20(2) 1050–1060. DOI:<a href=\"https://doi.org/10.1021/acs.molpharmaceut.2c00788\">10.1021/acs.molpharmaceut.2c00788</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36583623/\">https://pubmed.ncbi.nlm.nih.gov/36583623</a></p></li><li><p>Aras, O, et al., &amp; Sayman, HB (2021). Small Molecule, Multimodal, [. <i>Clinical genitourinary cancer</i> 19(5) 405–416. DOI:<a href=\"https://doi.org/10.1016/j.clgc.2021.03.011\">10.1016/j.clgc.2021.03.011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33879400/\">https://pubmed.ncbi.nlm.nih.gov/33879400</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Psma100718f;
